Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.
News|Articles|September 17, 2026
Dr. Dina Khalaf Breaks Down 3 Trials Advancing AML, MDS Care
Author(s)Spencer Feldman
Fact checked by: CURE staff
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Advertisement
Advertisement
In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology, discusses three clinical trials advancing treatment for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 AML/AMLSG 37-25.
Related to this article
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Endoscopic nipple-sparing mastectomy may improve recovery, reduce scarring and support quality of life for people undergoing breast cancer surgery.
Bern Paul uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.
In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.
Advertisement
Advertisement